Spevigo is a medicine that acts on the immune system. It is used in adults and adolescents from 12 years of age to prevent and treat flare-ups (recurrence or worsening) of generalised pustular psoriasis, an inflammatory skin disease causing pustules (pus-filled lesions) to appear over large areas of skin. Spevigo contains the active substance spesolimab.
Therapeutic Indication
### Therapeutic indication Spevigo is indicated for the prevention of generalised pustular psoriasis (GPP) flares in adults and adolescents from 12 years of age. Spevigo is indicated for the treatment of generalised pustular psoriasis (GPP) flares in adults and adolescents from 12 years of age as monotherapy.
Therapeutic Area (MeSH)
ATC Code
L04AC22
ATC Item
spesolimab
Pharmacotherapeutic Group
Immunosuppressants
Active Substance (Summary)
INN / Common Names
EMA Name
Spevigo
Medicine Name
Spevigo
Aliases
N/ANo risk management plan link.
